<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189293</url>
  </required_header>
  <id_info>
    <org_study_id>1526-IMIQ</org_study_id>
    <secondary_id>2004-004654-19</secondary_id>
    <nct_id>NCT00189293</nct_id>
  </id_info>
  <brief_title>Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts</brief_title>
  <official_title>Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the recurrence rate following total clearance of
      external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications
      per week for 4 weeks) followed by ablative therapy (laser or electrocautery therapy) with
      that from just ablative therapy treatment alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the recurrence rate 24 weeks after ablative therapy in subjects with external
      genital warts trated with imiquimod, 3 applications per week for 4 weeks followed by ablative
      therapy versus vehicle, 3 applications per week for 4 weeks followed by ablative therapy. A
      recurrence is defined as the investoigator-assessed occurrence of lesion(s) within the
      baseline area cleared by the treatment: imiquimod/vehicle then ablative therapy (either the
      initial ablative therápy session (A0), or if required for complete clearance of baseline
      lesions, a second ablative therapy session (A2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recuurence rate 24 weeks after ablative therapy</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>n.a.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate at 4 and 12 weeks post ablation</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of EGW area</measure>
    <time_frame>4 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing and cosmetic outcome</measure>
    <time_frame>4, 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and general tolerability</measure>
    <time_frame>n.a.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of complete clearance after initial topical treatment</measure>
    <time_frame>up to 6 weeks after initial topical treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new lesions</measure>
    <time_frame>n.a.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imiquimod 5% cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>vehicle cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Imiquimod 5% cream three times per week for 4 weeks (1 sachet)
1 or 2 sachet(s)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vehicle cream</intervention_name>
    <description>vehicle cream three times per week for 4 weeks (1 sachet)
1 or 2 sachet(s)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with at least 1 visible genital or perianal wart

          -  Total wart area 1 to 40 square centimeters.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Known other sexually transmitted disease

          -  Evidence of a clinically significant immunodeficiency

          -  Evidence of unstable cardiovascular, pulmonary, hematological, hepatic, renal,
             endocrine, collagen vascular, neurological or gastrointestinal abnormality or disease.

          -  Treatment within the 4 weeks prior to the Randomization Visit with any of the
             following systemic or topical treatments: interferons, interferon inducers,
             immunomodulators, immunosuppressive drugs, antiviral drugs (except for systemic
             acyclovir, valacyclovir and famciclovir), cytotoxic drugs, investigational drugs, or
             any drugs known to have major organ toxicity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fausto Boselli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unità di Ginecologia Preventiva e Oncologica Università di Modena e Reggio Emilia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Ostetrica e Ginecologica Università Politecnica delle Marche</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ostetricia e Ginecologia Ospedale Cardinal Massaia</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Ginecologia Oncologica, RCCS Ospedale Oncologico</name>
      <address>
        <city>Bari</city>
        <zip>70100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Autonomo di Diagnosi Precoce dei Tumori Ginecologici Ospedale Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ostetrica Ginecologica, Ospedale Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa Oncologia Chirurgica C Istituto Scientifico dei Tumori IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio di Ginecologia Preventiva, Istituti Clinici di Perfezionamento</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ostetrica Ginecologica Azienda Ospedaliera L. Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Ginecologia Preventiva e Oncologica Università di Modena e Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Ginecologia Oncologica, Ospedale Oncologico M. Ascoli</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostetricia e Ginecologia, Ospedale S. Maria delle Grazie</name>
      <address>
        <city>Pozzuoli</city>
        <zip>80078</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulatorio di Colposcopia e Patologia Cervico-Vaginale, Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joachim Maus, MD, Director Clinical Development</name_title>
    <organization>Meda Pharma GmbH &amp; Co. KG</organization>
  </responsible_party>
  <keyword>External Ano-Genital Warts</keyword>
  <keyword>Ablative Therapy</keyword>
  <keyword>Aldara</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

